<DOC>
	<DOCNO>NCT01855230</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , clinical activity ASM-024 administer dry powder inhalation formulation patient GOLD 2 GOLD 3 COPD .</brief_summary>
	<brief_title>Safety , Tolerability , Clinical Activity ASM-024 Administered Patients With GOLD 2 GOLD 3 Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This Phase II , randomize , double-blind , placebo-controlled , two-way crossover study evaluate safety , tolerability , clinical activity new , dry powder inhalation formulation ASM-024 administer twice daily 14 day patient GOLD-2 GOLD-3 COPD .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female adult age 40 yr clinically confirm diagnosis COPD severity stage GOLD 2 ( moderate ) 3 ( severe ) ; Stable COPD 1 month prior screen Stable smoker least three month prior screen , nonsmoker , smoke history ≥ 10 pack year ; FEV₁ ≥ 30 % &lt; 70 % predict normal value ; Normal 12lead ECG Clinically significant illness except COPD surgery within 8 week prior first administration study medication ; Significant medical history , Investigator 's opinion , may adversely affect participation ; History allergy significant adverse reaction drug similar ASM024 , nicotine , cholinergic drug drug similar chemical structure ; History hypersensitivity ( anaphylaxis , angioedema ) drug ; Positive pregnancy test female subject ; Use medication know prolong QT/QTc interval ; Clinically significant 12 lead ECG screening ; Clinically significant physical examination laboratory finding abnormal vital sign ; History alcohol drug abuse ; Positive hepatitis B C HIV test Screening ; Investigational drug within 30 day Screening ; longacting investigational drug within 90 day screen ; Previous exposure ASM024 ; Women childbearing potential male participant unwilling unable use accept method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>